health-policy5.43 min read
Medicare GLP-1 Discount Misses the Very Sick It Aims to Help
22 minutes ago•Source: KFF Health News
Health Policy News
The latest health policy stories, summarized by AI
Featured Health Policy Stories
View original source
11.645 min•3 days ago
Most states pass on Trump’s discounted GLP-1 deal, tightening Medicaid access
Trump’s plan to negotiate discounted GLP-1 weight‑loss drugs for Medicaid has stalled: only Indiana has signed on, while 29 states will not participate due to tight budgets. Twelve states still cover GLP-1s, but five of those recently ended coverage (California, Massachusetts, New Hampshire, Pennsylvania and South Carolina), with Rhode Island set to end in October. As other states weigh participation, many cite cost concerns and the risk to budget sustainability, meaning access to these drugs for low-income Americans on Medicaid is shrinking even as some argue these medications could reduce long-term health costs.
More Health Policy Stories
FDA Panel Backs Six Peptides for Compounding, But Legal Access Hangs on Rulemaking
An FDA Pharmacy Compounding Advisory Committee narrowly recommended six of seven peptides for inclusion on the 503A Bulks List—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—with emideltide rejected. The vote advances a nonbinding advisory step, but none of the substances is FDA-approved and final access hinges on proposed and final rulemaking. Available studies are short and small, leaving safety and efficacy data weak. The panel's reconstitution drew scrutiny over conflicts of interest, and payers should expect continued out-of-pocket use and online sourcing, with emphasis on careful medication reconciliation and safety monitoring until more data are available.
No Surprises Act Under Fire Over Arbitration Woes
The No Surprises Act has protected patients from surprise bills, but arbitration payouts have ballooned—2.5 million claims last year and about $15 billion in awards—fueling a stalemate between doctors and insurers over fixes. Lawmakers across the aisle say action is needed, but consensus remains elusive: Rep. Greg Murphy seeks harsher penalties on insurers who don’t pay arbitration judgments, insurers push back against overreach, and CMS has issued rules to streamline the process while advocates argue broader reform is still required.
Judge lets Medicaid work-rule for chronically ill patients move forward, with future challenges possible
A federal judge declined to block the rule requiring chronically ill Medicaid beneficiaries to prove they can’t work to keep coverage, keeping the policy in place ahead of a Jan. 1 implementation as the broader legal challenge continues; injunction denied without prejudice, allowing renewed challenges if new harms surface, while doctors warn of administrative burdens and potential impacts on patient care.
Court fight over Medicaid work rules hinges on who’s too sick to work
Democratic attorneys general and the Justice Department are challenging a Trump-era rule that would require Medicaid expansion adults to work 80 hours a month, arguing that a cancer diagnosis or other illnesses aren’t enough to exempt someone and that the rule is too vague on how to judge medical frailty. The Boston court ruling could determine who must work, volunteer, or study to keep coverage and how states verify exemptions, amid a rocky rollout (notably Nebraska) and concerns about administrative burden. The policy aims to curb costs ahead of the 2027-2028 rollout and becomes a focal point in the broader political fight over Obamacare’s Medicaid expansion.
CPSC Pushes Hospitals to Share ER Records with Private Contractor
The Consumer Product Safety Commission is pressuring major hospitals to share identifiable emergency-room records with Konza Health for a nationwide injury surveillance system, potentially involving 100 hospitals by year end; critics say the move exceeds the agency's authority and threatens patient privacy, raising questions about the legal process, data security, and the role of a private contractor in handling sensitive medical information.
Kennedy pushes peptide access as FDA panel weighs compounding route
An FDA advisory panel appointed by Health Secretary RFK Jr. recommended allowing licensed compounding pharmacies to produce several peptides with prescriptions, signaling a shift away from the FDA’s caution over safety and efficacy. Supporters argue it would curb a thriving unregulated market and expand patient access via providers, while critics warn it could bypass formal FDA review and safety safeguards. The final decision remains with the FDA, though Kennedy has authority to overrule agency conclusions, potentially reshaping the peptide market and care options.
US presses deprescribing drive to curb antidepressant use
Health Secretary RFK Jr. is advancing a deprescribing initiative to reduce antidepressant use. Federal officials and mental health professionals gathered to draft forthcoming clinical guidance on tapering SSRIs and expanding nonmedication options like therapy, while highlighting gaps in research on withdrawal symptoms and relapse versus recurrence of depressive symptoms.
Medicare's $50 GLP-1 Plan Targets Seniors, But With Limitations
Medicare launches an 18-month GLP-1 Bridge program outside Part D to offer eligible beneficiaries $50-a-month copays for certain weight‑loss drugs (Foundayo tablets, Wegovy, Zepbound) ending Dec 31, 2027. Eligibility is based on BMI and specific health conditions, and prescriptions can be issued even if the doctor doesn’t take Medicare, but some diabetics and individuals with sleep apnea or fatty liver may still face higher costs under Part D. Medicare covers about $245 of the drug cost minus the $50 copay, potentially leaving a total outlay of up to roughly $900 over 18 months for a participant, with no low-income subsidy. Total taxpayer cost is projected at $1.3 billion to $10 billion depending on uptake. The program could boost access but may strain clinics and lacks long-term funding certainty.
Federal Lyme plan risks cementing a false diagnosis, warns op-ed
An op-ed argues the new federal Lyme plan could validate misdiagnoses by steering patients to ILADS clinicians and framing Lyme as an infection-associated chronic illness, despite evidence that many positive tests (like isolated IgM or non-specific Western blots) are false and that genuine Lyme disease is geographically concentrated; the piece warns that long antibiotic courses can harm patients and calls for careful, evidence-based diagnosis instead of expanding a system built around a disputed syndrome.
Medicare to require hospitals to log end-of-life preferences in electronic records by 2028
Medicare proposes hospitals begin recording adults’ end-of-life care preferences (including DNR orders and designated decision-makers) in electronic health records by 2028, with these preferences part of quality metrics that could affect reimbursements from 2030. The goal is to normalize advance care planning and reduce unwanted, costly interventions, though providers warn about added burden and studies show mixed effects on care and outcomes.